ArticleBrain communications2023
Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis.
Article in Brain communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.Journal of neurology · 2024Pooled it
- Clinical approach to neurological paraneoplastic syndromes.Internal medicine journal · 2026Review
- Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome.Breast cancer research : BCR · 2026Article
- Progressive disability but survival advantage in anti-Hu/ANNA1 paraneoplastic neurological syndromes.Journal of neurology · 2026Article
- Dysautonomia and dysosmia associated with anti-Hu antibodies induced by immune checkpoint inhibitors: a case report.BMC neurology · 2026Article
- Epilepsia partialis continua may be a rare electroclinical feature of anti-Hu encephalitis: a pediatric case report.Frontiers in pediatrics · 2026Article
- Editorial: Toward predictive and mechanistic approaches for precision neuroimmunotoxicology.Frontiers in immunology · 2026Article
- Autoimmune encephalitis.Nature reviews. Disease primers · 2025Review
- Immune Checkpoint Inhibitors Trigger and Exacerbate Anti-CV2/CRMP5 Paraneoplastic Neurologic Syndromes.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.Journal of neurology · 2025Article
- Article
- Neurodegeneration and the immune system: lessons from autoimmune encephalitis.Journal of neurology · 2025Review
- Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis.Annals of clinical and translational neurology · 2025Article
- Anti-PD1-/PDL1-induced chronic intestinal pseudo-obstruction: three cases treated with vedolizumab after corticosteroid failure with mixed results.Cancer immunology, immunotherapy : CII · 2025Article
- Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes with Progressive Supranuclear Palsy-like Manifestations.Brain sciences · 2024Review
- Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.The Lancet regional health. Europe · 2024Article
- Complexities in the Diagnosis and Management of Anti-Hu Antibody-Associated Paraneoplastic Syndrome.Cureus · 2024Article
- Dysautonomia in anti-Hu paraneoplastic neurological syndromes.Journal of neurology · 2024Article
- Focal Seizures Induced by Paraneoplastic Syndrome Leading to a Diagnosis of Small Cell Lung Carcinoma.Cureus · 2024Article
- Predicting disability and mortality in CV2/CRMP5-IgG associated paraneoplastic neurologic disorders.Annals of clinical and translational neurology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-Hu are the most frequent antibodies in paraneoplastic neurological syndromes, mainly associated with an often limited stage small cell lung cancer. The clinical presentation is pleomorphic, frequently multifocal. Although the predominant phenotypes are well characterized, how different neurological syndromes associate is unclear. Likewise, no specific study assessed the performance of new-generation CT and PET scanners for cancer screening in these patients. Herein, we aimed to describe the clinical pattern and cancer screening in a retrospective cohort of 466 patients with anti-Hu autoimmunity from the French Reference Centre on Paraneoplastic Neurological Syndromes registry. Clinical presentation, cancer screening and diagnosis were analysed. Among the 466 patients, 220 (54%) had multifocal neurological involvement. A hierarchical cluster analysis grouped the patients into (i) mainly limbic encephalitis, (ii) predominantly peripheral neuropathy and (iii) broad involvement of the nervous system (mixed group). Compared with limbic encephalitis and mixed groups, patients in the neuropathy group more frequently had a chronic onset of symptoms (29 versus 13 and 17%), elevated CSF proteins (83 versus 47 and 67%) and died from cancer progression (67 versus 15 and 28%; all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.